Trial · NCT01440192
Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis
NCT01440192, Phase 1, Terminated, Celularity Incorporated
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis. Trials, record NCT01440192. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01440192
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis
- NCT number
- NCT01440192
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 4 participants, actual
- Lead sponsor
- Celularity Incorporated
- Conditions
- Stage 2 Pulmonary Sarcoidosis, Stage 3 Pulmonary Sarcoidosis
- Interventions
- PDA001 (cenplacel-L)
- First posted
- 2011-09-26
- Last updated
- 2018-03-01
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate pulmonary artery pressure during infusion | Day 1 | Evaluate pulmonary artery pressure during infusion |
| Primary | Adverse Events | 24 months ( 2 years) from first dose - Study Day 1 | Number of Participants experiencing adverse events during the initial and extended follow-up periods |
| Primary | Evaluate pulse oximetry during infusion | Day 1 and Day 8 | Evaluate pulse oximetry during infusion on Day 1 and on Day 8. |
| Secondary | Change from baseline thru study day 731 in forced vital capacity (FVC) | 24 months ( 2 years) from first dose - Study Day 1 | Change from baseline thru study day 731 in forced vital capacity (FVC) |
| Secondary | Change from baseline thru study day 731 in forced expiratory volume (FEV1) | 24 months ( 2 years) from first dose - Study Day 1 | Change from baseline thru study day 731 in forced expiratory volume (FEV1) |
| Secondary | Change from baseline thru study day 731 in diffusing capacity of the lung for carbon monoxide (DLCO) | 24 months ( 2 years) from first dose - Study Day 1 | Change from baseline thru study day 731 in diffusing capacity of the lung for carbon monoxide (DLCO) |
| Secondary | Change from baseline thru study day 731 in 6 minute walk test (6MWT) | 24 months ( 2 years) from first dose - Study Day 1 | Change from baseline thru study day 731 in 6 minute walk test (6MWT) |
| Secondary | Change from baseline thru study day 731 in St. George's Respiratory Questionnaire (SGRQ). | 24 months ( 2 years) from first dose - Study Day 1 | Change from baseline thru study day 731 in St. George's Respiratory Questionnaire (SGRQ). |
| Secondary | Change from baseline thru study day 731 in Fatigue Assessment Score (FAS) | 24 months ( 2 years) from first dose - Study Day 1 | Change from baseline thru study day 731 in Fatigue Assessment Score (FAS) |
| Secondary | Change from baseline thru study day 731 in baseline dyspnea index (BDI)/ transitional dyspnea index (TBI | 24 months ( 2 years) from first dose - Study Day 1 | Change from baseline thru study day 731 in baseline dyspnea index (BDI)/ transitional dyspnea index (TBI |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01440192
GET https://conductscience.org/api/trials/v1/NCT01440192/registered